Study: NCT02735252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataNGS
Description: CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added